U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07813039) titled 'A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation' on Sept. 04.
Brief Summary: The purpose of this study is to evaluate the relative bioavailability of VX-581 tablet formulation compared to a suspension formulation along with its safety and tolerability.
Study Start Date: Sept. 07
Study Type: INTERVENTIONAL
Condition:
Cystic Fibrosis
Intervention:
DRUG: VX-581
Tablet and Suspension for Oral Administration.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vertex Pharmaceuticals Incorporated
Published by HT Digital Content Services with permission from Health Daily Digest....